Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Lincoln Pharmaceuticals Limited (NSE: LINCOLN), ISIN INE405C01035 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
LINCOLN last traded at ₹603.55 (+1.55%), with a 52-week range of ₹439.95 to ₹770.00 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 49.78%, FIIs 4.60%, DIIs 0.27%, mutual funds 0.00%.
EquiSense Score (ECS): 76/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.